Antiviral Activity

Lead HIV Product Protects Mice from HIV Infection

Published in AIDS Weekly, April 27th, 1998

Progenics Pharmaceuticals, Inc., Tarrytown, New York, announced that PRO 542 demonstrated potent antiviral activity in an animal model of HIV infection.

The results were published in the April 1998 issue of the Journal of Virology (vol. 72, no. 4). PRO 542 is an antibody-like molecule that is designed to selectively target HIV and prevent the virus from infecting healthy immune system cells. PRO 542 is being developed both to treat and prevent HIV infection.

In the study, PRO 542 protected animals against infection by clinical HIV strains isolated from HIV infected individuals. The study used the hu-PBL-SCID mouse model of HIV infection, the only...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1998-04-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry